Health Economics

Key Data:

Country-specific total annualised direct cost (TADC)

Country UK – N=2,347 Spain – N=1,949 France – N=1,221 Italy – N=1,518 Germany – N=2,823
Cost Mean (SEM) (£) % Mean (SEM) (€) % Mean (SEM) (€) % Mean (SEM) (€) % Mean (SEM) (€) %
Drug 113 (4.9) 4.0 136.7 (5.5) 11.0 369.2 (13.6) 21.7 106.2 (5.3) 6.9 277.9 (6.6) 11.1
Inpatient 2,118.3 (186.0) 74.1 793.5 (127.6) 63.9 1,109.9 (180.1) 65.2 1,294.7 (362.4) 83.7 1,968.5 (166.1) 78.6
Outpatient 625.5 (16.6) 21.9 311.0 (26.1) 25.1 222.9 (18.8) 13.1 145.9 (25.7) 9.4 257.6 (76.0) 10.3
Total 2,857.3 (187.8) 100 1,241.2 (131.7) 100 1,702.0 (181.2) 100 1,546.8 (363.4) 100 2,504.1 (183.4) 100

AF imposes a high financial, economic and human burden to society. Based on population dynamics, the burden is likely to grow in the future.

 

Key Abstracts: 

The burden of atrial fibrillation in the more populated European countries: perspectives from the GARFIELD-AF registry. European Society of Cardiology (Barcelona, Spain, 26th August -30th August 2017) – Mantovani L et al  and on behalf of GARFIELD-AF.

Global status

Read more
Total patients 57,262
Recruitment Recruitment closed
Follow-up Ongoing
Study end: 2018

Members Login

Coming soon… If you would like to be notified of when this is available click here and add your details to receive updates

Newsletter Signup






Please see our Privacy Policy and Cookie Policy

Contact Us

To find out more about GARFIELD-AF, please contact the Thrombosis Research Institute

E: garfield@tri-london.ac.uk
T: 0203 198 9947